Peroxisome Dysfunction Validation in Parkinson's Disease

V2, Crosslink

🧫

Peroxisome Dysfunction Validation in Parkinson's Disease

active

experiment Created: 2026-04-02T10:01:41 By: crosslink-v2 Quality: 67% ✓ SciDEX ID: experiment-exp-wiki-experiments-peroxiso

🧫 Experiment Protocol Clinicalproposed

SUMMARY

# Peroxisome Dysfunction Validation in Parkinson's Disease ## Background and Rationale This clinical investigation tests the hypothesis that peroxisome dysfunction represents an upstream pathogenic driver in Parkinson's disease, contributing to oxidative stress, lipid metabolism disruption, and neuroinflammation. The study employs a multi-modal approach combining advanced metabolomics, proteomics, and functional cellular assays to characterize peroxisome-related biomarkers in PD patients. Partic

METHODOLOGY NOTES

**Phase 1: Participant Recruitment and Baseline Assessment (Months 1-3)** • Recruit 150 PD patients (Hoehn & Yahr stages 1-3) from movement disorder clinics • Recruit 75 age-matched healthy controls • Obtain informed consent and perform comprehensive neurological evaluation • Collect medical history, medication records, and family history • Perform MDS-UPDRS Parts I-IV assessments • Collect baseline blood samples (50mL) and CSF samples (10mL) via lumbar puncture **Phase 2: Peroxisome Function Assessment (Months 2-4)** • Measure plasma very long-chain fatty acids (VLCFA) using GC-MS • Quantify pristanic and phytanic acid levels via LC-MS/MS • Assess bile acid synthesis intermediates (DHCA, THCA) in plasma • Evaluate catalase activity in peripheral blood mononuclear cells • Measure plasmalogen levels (16:0, 18:0, 18:1) in erythrocyte membranes • Quantify peroxisomal β-oxidation capacity using cultured skin fibroblasts **Phase 3: Alpha-Synuclein and Inflammatory Markers (Months 3-5)** •

▸Metadatasource: {'type': 'manual', 'source_name': 'wiki'

source	{'type': 'manual', 'source_name': 'wiki', 'extracted_by': 'backfill_v1', 'extraction_date': '2026-04-16T01:00:16.904432Z'}
summary	# Peroxisome Dysfunction Validation in Parkinson's Disease ## Background and Rationale This clinical investigation tests the hypothesis that peroxisome dysfunction represents an upstream pathogenic dr
entities	{'genes': ['DGAT1/GPX4/PLIN2'], 'diseases': ["Parkinson's Disease"]}
model_system	human
_schema_version	1
experiment_type	clinical
primary_outcome	Significant elevation in plasma very-long-chain fatty acids (C24:0 and C26:0) and reduction in plasmalogens in PD patients compared to controls, with correlation to disease severity measured by MDS-UP
methodology_notes	Phase 1: Participant Recruitment and Baseline Assessment (Months 1-3) • Recruit 150 PD patients (Hoehn & Yahr stages 1-3) from movement disorder clinics • Recruit 75 age-matched healthy controls •
replication_status	single_study
extraction_metadata	{'backfill_at': '2026-04-16T01:00:16.904439', 'needs_review': True, 'extraction_notes': 'Backfilled from wiki source (no PMID available)', 'extraction_confidence': 0.4}

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

746

Outgoing

661

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Peroxisome Dysfunction Validation in Parkinson's Disease

derives from (16)

supports (55)

💬 Discussion